Administration of nusinersen via paramedian approach for spinal muscular atrophy
Brain and Development2020Vol. 43(1), pp. 121–126
Citations Over Time
Hideyuki Iwayama, Norimitsu Wakao, Hirokazu Kurahashi, Norika Kubota, Ayako Hattori, Toshiyuki Kumagai, Akihisa Okumura
Abstract
Intrathecal administration of nusinersen via the paramedian approach had the advantages of a high success rate and short procedure time with fewer adverse events in SMA patients associated with scoliosis.
Related Papers
- → P.362RAINBOWFISH: A study of risdiplam (RG7916) in newborns with pre-symptomatic spinal muscular atrophy (SMA)(2019)8 cited
- → Recent research on the treatment of spinal muscular atrophy.(2022)2 cited
- → Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): results of the phase 3 CHERISH study(2017)1 cited
- → Perspectives on models of spinal muscular atrophy for drug discovery(2004)17 cited
- → Therapeutic decisions under uncertainty in spinal muscular atrophy (decisions-SMA study): A research protocol(2021)